52883
  • Log in
The Daily Sceptic
No Result
View All Result
  • Articles
  • About
  • Archive
    • ARCHIVE
    • NEWS ROUND-UPS
  • Forum
  • Donate
  • Newsletter
The Daily Sceptic
No Result
View All Result

What’s the Truth About Budesonide?

by Will Jones
13 April 2021 11:31 PM
What’s the Truth About Budesonide?

Since Lockdown Sceptics reported on Sunday about the remarkable effectiveness of the common asthma treatment Budesonide against COVID-19 – cutting serious disease by 90% according to a study published in the Lancet – a new study has appeared underlining its effectiveness as a Covid treatment.

The first study was part of the STOIC trial at Oxford University and found that 10 of the 73 symptomatic Covid patients in the control group required urgent medical care (e.g. hospitalisation) compared to just one of the 73 symptomatic Covid patients who inhaled Budesonide twice a day. This translates to 87% effectiveness in preventing serious disease. One limitation of the study was that few of the participants were high risk or elderly, with an average age of 45; another was that it was small.

The new study is from the PRINCIPLE trial, also based at Oxford, and uses a larger group (751 using Budesonide, 1,028 in the control group), all of whom are either over 65 or over 50 with a risk-increasing underlying health condition. It found that Budesonide reduced a patient’s time to recovery by an average of three days (11 days compared to 14), and also reduced the chances of a relapse within 28 days.

Disappointingly, however, those who took Budesonide were only slightly less likely to be admitted to hospital – 8.5% compared with 10.3% – and this result was not statistically significant (though the trial is to be expanded which may address this issue).

Professor Richard Hobbs of Oxford University, who co-leads the trial, said: “For the first time we have high-quality evidence of an effective treatment that can be rolled out across the community for people who are at most risk of developing more severe illness from COVID-19. Unlike other proven treatments, Budesonide is effective as a treatment at home and during the early stages of the illness. This is a significant milestone for this pandemic and a major achievement for community-based research.”

On Monday, an alert was sent to the NHS saying the drug can now be used off-label for the treatment of COVID-19 for the over-65s and at-risk over-50s, the Telegraph reports.

This is good news. However, not everyone is convinced. The ‘Swiss Doctor’ notes that the trials have financial ties to Budesonide manufacturer AstraZeneca, and that the results are not as impressive as the newspaper reports might suggest. For example, they use “soft” rather than “hard” endpoints.

In both trials, Budesonide achieved no significant improvement in any “hard endpoint”: in the PRINCIPLE trial, there was no significant difference in hospitalisations, deaths, hospital assessment without admission, oxygen administration, and ICU admission. In the Oxford [STOIC] trial, there was no significant difference in the proportion of people and days with an oxygen saturation below 94%, PCR cycle threshold increase, and FluPRO-measured symptom resolution.

The “soft” endpoints were “self-reported recovery” in PRINCIPLE and “urgent care visits” in STOIC, of which only one patient was actually hospitalised and required oxygen.

The ‘Swiss Doctor’ does concede that there was some indication of benefit to the high-risk in the PRINCIPLE trial: hospitalisation/death risk was lower (8.5% vs 10.3%), oxygen requirement was lower (5.8% vs 8.4%), and ICU admission was lower (1.2% vs 2.2%). However, the trial will need to expand if these differences are to gain statistical significance.

The positive results for Budesonide are certainly welcome, as is the news that the NHS has been given the green light to prescribe it for high-risk groups. Though why not for the low risk under-65s as well? In the STOIC trial it cut the need for urgent care to close to zero in that group. Is that not a worthwhile medical intervention, particularly with all the worry about ‘long Covid’?

It’s fair to say that the 17% reduction in hospitalisation/death among the high risk is disappointing when compared to the impressive 87% reduction in urgent care among the low risk. But it’s still an improvement, and the other indicators – shorter recovery time, reduced need for oxygen and intensive care – are also encouraging.

I should add that what we’re really waiting for are high quality results on the highly promising Ivermectin that are deemed acceptable to the health regulators so that drug can become generally available. No rush, guys. Not like people are dying or anything.

Tags: BudesonideTreatments

Donate

We depend on your donations to keep this site going. Please give what you can.

Donate Today

Comment on this Article

You’ll need to set up an account to comment if you don’t already have one. We ask for a minimum donation of £5 if you'd like to make a comment or post in our Forums.

Sign Up
Previous Post

Quarter of Covid Deaths Not Caused by Virus

Next Post

News Round Up

Subscribe
Login
Notify of
Please log in to comment

Profanity and abuse will be removed and may lead to a permanent ban.

12 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments

NEWSLETTER

To view today's newsletter click here

To receive our latest news in the form of a daily email, enter your details here:

DONATE

LISTED ARTICLES

  • Most Read
  • Most Commented
  • Editors Picks

News Round-Up

1 July 2022
by Will Jones
Confessions of a Conservative Rebel

Confessions of a Conservative Rebel

1 July 2022
by Nick Dixon
Scottish Fertility Clinic Bans Unvaccinated Women From Using Services as Italy Announces Mandatory Vaccination for Over-50s

What’s Behind the Worldwide Drop in Birth Rates, Nine Months After the Vaccination Rollouts to Younger People?

29 June 2022
by Nick Bowler
Pfizer Set to Seek Approval for Its Covid Vaccine in U.S. Babies This Winter

The Case Against Vaccinating Children Against Covid

30 June 2022
by Will Jones
How Governments Bullied Us During the Pandemic

How Governments Bullied Us During the Pandemic

1 July 2022
by Susan Broomhall

News Round-Up

15
Confessions of a Conservative Rebel

Confessions of a Conservative Rebel

15
Halifax Customers Close Accounts in Response to Gender Pronouns Fiasco

Halifax Customers Close Accounts in Response to Gender Pronouns Fiasco

9
Pfizer Set to Seek Approval for Its Covid Vaccine in U.S. Babies This Winter

The Case Against Vaccinating Children Against Covid

14
Scottish Fertility Clinic Bans Unvaccinated Women From Using Services as Italy Announces Mandatory Vaccination for Over-50s

What’s Behind the Worldwide Drop in Birth Rates, Nine Months After the Vaccination Rollouts to Younger People?

25
How Governments Bullied Us During the Pandemic

How Governments Bullied Us During the Pandemic

1 July 2022
by Susan Broomhall
Pfizer Set to Seek Approval for Its Covid Vaccine in U.S. Babies This Winter

The Case Against Vaccinating Children Against Covid

30 June 2022
by Will Jones
Letter From a Teacher to the Conservative Party About Mask Mandates in Classrooms

Children Need to be Taught to See Through The Lies

30 June 2022
by Mark Shaw
ONS Data Suggest Vaccine Effectiveness Against Death Has Been Overestimated

ONS Data Suggest Vaccine Effectiveness Against Death Has Been Overestimated

30 June 2022
by Nick Rendell
Scottish Fertility Clinic Bans Unvaccinated Women From Using Services as Italy Announces Mandatory Vaccination for Over-50s

What’s Behind the Worldwide Drop in Birth Rates, Nine Months After the Vaccination Rollouts to Younger People?

29 June 2022
by Nick Bowler

POSTS BY DATE

April 2021
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  
« Mar   May »

SOCIAL LINKS

Free Speech Union
The Daily Sceptic
  • Home
  • About us
  • Donate
  • Privacy Policy

Facebook

Twitter

Instagram

RSS

Subscribe to our newsletter

© 2022 Skeptics Ltd.

No Result
View All Result
  • Articles
  • About
  • Archive
    • ARCHIVE
    • NEWS ROUND-UPS
  • Forum
  • Donate
  • Newsletter

© 2022 Daily Sceptic.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Please note: To be able to comment on our articles you'll need to be a registered donor

Already have an account?
Please click here to login Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
wpDiscuz
You are going to send email to

Move Comment